Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 13/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912535 | 0.98 | DUT (0.55) | DUTNAAAL3MBTL1PDE3A | |
| SCHEMBL4957852 | 0.93 | DUT (0.55) | DUTNAAAL3MBTL1PDE3A | |
| SCHEMBL2990980 | 0.85 | L3MBTL1 (0.53) | DUTL3MBTL1 | |
| SCHEMBL30903389 | 0.83 | DUT (0.58) | DUTNAAAL3MBTL1PDE3A | |
| SCHEMBL25368590 | 0.83 | NAAA (0.54) | DUTNAAAL3MBTL1PDE3A | |
| SCHEMBL17372138 | 0.83 | DUT (0.55) | DUTNAAA | |
| SCHEMBL913034 | 0.83 | NAAA (0.54) | DUTNAAAL3MBTL1PDE3A | |
| SCHEMBL7181572 | 0.83 | DUT (0.54) | DUTNAAAL3MBTL1PDE3A | |
| SCHEMBL24205032 | 0.83 | NAAA (0.54) | DUTNAAAL3MBTL1PDE3A | |
| SCHEMBL913371 | 0.83 | NAAA (0.54) | DUTNAAAL3MBTL1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051575-A | Detection of modified nucleobases in nucleic acid samples | 豪夫迈·罗氏有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-2342616-A2 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | Alnylam Pharmaceuticals Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010039548-A2 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7582748-B2 | efficient synthetic route to an optionally protected 1-halo-2-deoxyribose; formation of an alkyl acetal, such as a methyl acetal, of a furanose, such as 2-deoxyribose, optionally protecting the remaining hydroxyl groups of the furanose, reacting the acetal with an acyl halide that forms the acid halide | MICROBIOLOGICA QUIMICA E FARMACEUTICAL LTD. (BR) | 2009-09-01 | — | — | US | disclosed |
| EP-1745573-A2 | METHODS OF MANUFACTURE OF 2 -DEOXY-&bgr;-L-NUCLEOSIDES | Microbiologica Quimica E Farmaceutica Ltd. (BR) | 2007-01-24 | — | — | EP | disclosed |
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-12-30 | — | — | US | disclosed |
| WO-2004084453-A2 | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | DUT, DAO, DCTD | DUT 1/4885NAAA 107/4885L3MBTL1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.